Related references
Note: Only part of the references are listed.The Therapeutic Potential of LRRK2 and alpha-Synuclein in Parkinson's Disease
Saurabh Sen et al.
ANTIOXIDANTS & REDOX SIGNALING (2009)
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease
Saskia Biskup et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2009)
The Ste5 Scaffold Directs Mating Signaling by Catalytically Unlocking the Fus3 MAP Kinase for Activation
Matthew Good et al.
CELL (2009)
Heat Shock Protein 90 as a Drug Target: Some Like It Hot
Udai Banerji
CLINICAL CANCER RESEARCH (2009)
LRRK2 in Parkinson's disease: biochemical functions
Vasanti S. Anand et al.
FEBS JOURNAL (2009)
LRRK2 in Parkinson's disease: genetic and clinical studies from patients
Udhaya Kumari et al.
FEBS JOURNAL (2009)
The Death Domain of FADD Is Essential for Embryogenesis, Lymphocyte Development, and Proliferation
Hongxia Z. Imtiyaz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro
Christian Johannes Gloeckner et al.
JOURNAL OF NEUROCHEMISTRY (2009)
The Parkinson Disease Protein Leucine-Rich Repeat Kinase 2 Transduces Death Signals via Fas-Associated Protein with Death Domain and Caspase-8 in a Cellular Model of Neurodegeneration
Cherry Cheng-Ying Ho et al.
JOURNAL OF NEUROSCIENCE (2009)
Transmembrane Helix of Novel Oncogene with Kinase-Domain (NOK) Influences Its Oligomerization and Limits the Activation of RAS/MAPK Signaling
Ying-Hua Li et al.
MOLECULES AND CELLS (2009)
CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity
Han Seok Ko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila
Yuzuru Imai et al.
EMBO JOURNAL (2008)
Intramolecular Activation Mechanism of theDictyosteliumLRRK2 Homolog Roco Protein GbpC
Wouter N. van Egmond et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation
Elisa Greggio et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells
Edward D. Plowey et al.
JOURNAL OF NEUROCHEMISTRY (2008)
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2
Lizhen Wang et al.
JOURNAL OF NEUROSCIENCE (2008)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Daniel G. Healy et al.
LANCET NEUROLOGY (2008)
Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease
M. Westerlund et al.
NEUROSCIENCE (2008)
FLIP and the death effector domain family
J. W. Yu et al.
ONCOGENE (2008)
Caspases in apoptosis and beyond
J. Li et al.
ONCOGENE (2008)
Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase
Junpeng Deng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player
K. Haebig et al.
NEUROGENETICS (2008)
Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen
S. H. Y. Loh et al.
CELL DEATH AND DIFFERENTIATION (2008)
Dynamic and redundant regulation of LRRK2 and LRRK1 expression
Saskia Biskup et al.
BMC NEUROSCIENCE (2007)
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity
Mahaboobi Jaleel et al.
BIOCHEMICAL JOURNAL (2007)
Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain
Shinji Higashi et al.
BRAIN RESEARCH (2007)
Apoptotic mechanisms in mutant LRRK2-mediated cell death
Ciro Iaccarino et al.
HUMAN MOLECULAR GENETICS (2007)
MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease
Linda R. White et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2007)
Leucine-rich repeat kinase 2 associates with lipid rafts
Taku Hatano et al.
HUMAN MOLECULAR GENETICS (2007)
Molecular chaperones and protein kinase quality control
Avrom J. Caplan et al.
TRENDS IN CELL BIOLOGY (2007)
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity
Andrew B. West et al.
HUMAN MOLECULAR GENETICS (2007)
The familial parkinsonism gene LRRK2 regulates neurite process morphology
David MacLeod et al.
NEURON (2006)
Global, in vivo, and site-specific phosphorylation dynamics in signaling networks
Jesper V. Olsen et al.
CELL (2006)
Localization of LRRK2 to membranous and vesicular structures in mammalian brain
Saskia Biskup et al.
ANNALS OF NEUROLOGY (2006)
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Wanli W. Smith et al.
NATURE NEUROSCIENCE (2006)
The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf
Kenta Terai et al.
EMBO JOURNAL (2006)
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Elisa Greggio et al.
NEUROBIOLOGY OF DISEASE (2006)
LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain
D Korr et al.
CELLULAR SIGNALLING (2006)
Crystal structure of a viral FLIP - Insights into FLIP-mediated inhibition of death receptor signaling
FY Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Oligomerization states of the association domain and the holoenyzme of Ca2+/CaM kinase II
OS Rosenberg et al.
FEBS JOURNAL (2006)
Biochemical and pathological characterization of Lrrk2
BI Giasson et al.
ANNALS OF NEUROLOGY (2006)
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity
CJ Gloeckner et al.
HUMAN MOLECULAR GENETICS (2006)
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
OM Grbovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
SD Dias et al.
CANCER RESEARCH (2005)
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
AB West et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Coordinating ERK/MAPK signalling through scaffolds and inhibitors
W Kolch
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Oligomerization-induced differential dephosphorylation of c-Met receptor tyrosine kinase
PR Sheth et al.
BIOCHEMISTRY (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes
O Micheau et al.
CELL (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Apoptosome: The cellular engine for the activation of caspase-9
YG Shi
STRUCTURE (2002)
CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein
S Murata et al.
EMBO REPORTS (2001)
CHIP is a U-box-dependent E3 ubiquitin ligase -: Identification of Hsc70 as a target for ubiquitylation
JH Jiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family
AC Maroney et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
